Drugs / HCV E1E2/MF59
HCV E1E2/MF59
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00500747 | Aug 2003 → Aug 2005 | hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCV E1E2/MF59 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00500747 ↗ |
| Known as | HCV E1/E2/MF59 vaccine | “a vaccine (the HCV E1/E2/MF59 vaccine) against hepatitis C (HCV)” NCT00500747 ↗ |
| Known as | HCV E1E2 vaccine | “Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.” PMID 20619382 ↗ Jul 2010 |
| Modality | Vaccine | “The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59.” NCT00500747 ↗ |